HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer
Conditions
Brief summary
The purpose of this preliminary research study is to see if patients discontinuing maintenance Herceptin and/or other anti-HER-2 treatments with monitoring in addition to radiologic imaging and routine blood work will stay in complete radiological remission and to determine how long patients are able to stay in complete radiological remission without treatment.
Interventions
OTHERDiscontinuation of Anti-HER-2 Maintenance Treatment
Patients assigned to this group will be asked to discontinue anti-HER-2 maintenance treatment.
Sponsors
University of Miami
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with a diagnosis of HER-2 positive metastatic (Stage IV) breast cancer. 2. Patients in complete radiological remission (CRR), including a stable bone scan, as determined by computed tomography (CT), positron-emission tomography (PET), or PET-CT. a. Patients with brain metastasis are allowed to participate as long as their disease has been treated and radiologically stable for at least 36 months. 3. Patients must be on the same or current anti-HER-2 directed therapy for at least 36 months. 4. Archived tumor biopsy available. 5. Patients with no evidence of circulating tumor deoxyribonucleic acid (ctDNA) as determined by the Signatera assay. 6. Patients willing to stop maintenance anti-HER-2 directed therapy with close monitoring. 7. Patients with an Eastern Cooperative Oncology Group (ECOG) performance score from 0 to 2. 8. Patients ≥ 18 years of age. 9. Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
1. Patients with uncontrolled metastatic disease. 2. Patients whose disease has been controlled for less than 36 months on the same or current anti-HER-2 therapy. 3. Patients who are currently receiving or have received treatment for a secondary cancer other than resected non-melanoma skin cancer lesions or in situ cancer within the past 24 months. 4. Patients positive for ctDNA (which occurs when a patient's blood sample contains ≥2 target markers) with the Signatera assay. 5. Use of investigational drugs ≤ 28 days prior to study enrollment and during the study. 6. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or that makes participation in the trial to be not in the best interest of the patient in the opinion of the Investigator. 7. Patients with impaired decision-making capacity. Patients who are found to be ctDNA+ at study entry will be recorded as a screen failure (Section 5.4). Their Signatera testing results will be provided to their treating physician to aid in clinical decision-making for disease management and treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of maintaining remission after discontinuing use of anti-HER-2 | Up to 72 months | The feasibility of maintaining remission of HER-2 will be measured as the proportion of patients who discontinue anti-HER-2 therapy and who remain in remission is assessed by monitoring ctDNA in the blood. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ability of re-attain remission after ctDNA+ status | Up to 72 months | Ability to re-attain remission after ctDNA+ status is defined as returning to ctDNA- status within 6 months after testing ctDNA+ during the study. This is assessed by the monitoring of ctDNA in the blood of participants that have tested ctDNA positive after stopping anti-HER-2 maintenance therapy and chose to restart anti-HER-2 therapy. |
| Duration of response (DOR) | Up to 72 months | The duration of response (DOR) in study participants that have restarted anti-HER-2 therapy measures the time from is ctDNA+ status to overall response rate (ORR). This includes study participants that have ctDNA+ status and have chosen to either restart their previous anti-HER-2 maintenance therapy or have started a new anti-HER-2 therapy. The ORR is determined by blood and imaging monitoring. |
| Diagnostic Accuracy of ctDNA Monitoring Assay to Identify Disease Progression | Up to 72 months | Diagnostic accuracy is evaluated by comparing disease relapse and/or progression confirmed by imaging compared to study participants ctDNA status. |
Countries
United States
Contacts
Primary ContactElisa Krill Jackson, MD
Outcome results
None listed